Info@ThinkPinkRocks.com

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME show improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.

See the original article here:
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME show improvement in visual acuity

Share

Leave a Reply